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Letters
Should radiologists and 
pathologists talk to patients?
Ibrahim M Zardawi
Medical Director, Mayne Health, Laverty Pathology, 
Newcastle Laboratory, PO Box 801, Newcastle, NSW 
2300. ibrahim.zardawi@maynegroup.com
TO THE EDITOR: The practice of radiology
and pathology has changed dramatically in
the past two decades. Increased use of
multidisciplinary assessments and interven-
tional techniques has meant greater expo-
sure of patients to radiologists and
pathologists. When patients undergo inves-
tigations, they are invariably anxious, usu-
ally expect the worst, and want the result as
soon as possible. Therefore, there is
pressure to provide an immediate answer to
the problem at hand. In most instances, it
would be possible to offer a diagnosis.
However, many radiologists and patholo-
gists are reluctant to discuss investigations
with patients in detail.1
During interventional procedures, radiol-
ogists and pathologists see patients only
briefly; they often don’t know all the facts
about them, and are not ultimately respon-
sible for their clinical management.1 As the
patient is only temporarily in the care of the
radiologist or the pathologist, it is not
appropriate to discuss complex issues or
offer opinions and advice. Such advice may
put the patient’s doctor in an awkward
position, forcing the referring practitioner
to follow a course of action which may not
be in the best interests of the patient.
At a patient’s insistence, radiologists and
pathologists can sometimes indicate to
someone who has a clearly benign condition
that the problem under investigation is
unlikely to be serious.2-4 This may be the
case with screening mammography, as, in
most cases, the results are either normal or
indicate a non-malignant condition. How-
ever, in diagnostic radiology and pathology,
such an opinion is usually based on a
preliminary impression, which may change
when all the facts are considered.
The cost of providing on-the-spot written
reports to the patient has to be factored into
the equation. It has been estimated that the
additional cost of immediate reporting of
results of screening mammography is about
US$28.22. When additional equipment
and space were not required, the cost would
increase by US$4.38. Although most
patients in the study preferred immediate
reporting, they were unwilling to pay the
additional fees.5 With respect to pathology,
a formal fine-needle aspiration result can be
delivered within an hour, but, for the
reasons outlined above, this would not be
advisable. Further, the pathologist’s con-
tract is with the referring doctor and the
report is written in scientific language,
which may not be easily understood by the
patient, leading to unnecessary anxiety.
Giving bad news to a patient is not an
easy task even for trained professionals. It is
even harder for radiologists and patholo-
gists who are not generally equipped to
provide counselling and support, and who
may not be indemnified by their insurers to
carry out such tasks. Further, neither
radiology departments nor pathology labo-
ratories are suitable settings for giving bad
news,1 as very few support avenues are
usually available to patients there.
Predicting the impact that bad news will
have on a patient is extremely difficult, and
radiologists and pathologists should, for
compassionate and for medicolegal reasons,
refrain from providing immediate answers
to patients.
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TO THE EDITOR: Jamrozik’s editorial1
about our report of a failed randomised
controlled trial (RCT)2 in an Aboriginal
medical service helps to explain why
researchers might be reluctant to submit
articles describing unsuccessful trials, thus
limiting potential for the scientific commu-
nity to learn from such experiences. The
main point of our article was to describe the
manifest difficulties of implementing an
RCT — the evidence “gold standard” — in
this type of setting. Interestingly, Jamrozik
largely attributes these difficulties to incom-
petence or naivety (or both) on the part of
the researchers and funders, rather than to
complexities inherent in the study design,
the setting and the intervention.
A separately funded pilot study is, in
principle, a good idea, but extremely
difficult to get funding for in today’s
environment. Of course, we did conduct a
pilot — that, in fact, was what we reported
on — but it is unclear how this would have
helped us better estimate absolute preva-
lences and effect sizes for intervention and
control groups, as a substantial number of
participants, followed up for six months,
would have been needed to do this.
Nor is it clear how taking a population
approach and distributing guidelines to all
drinkers rather than offering personalised
advice to hazardous drinkers would have
helped — firstly, because we were specifi-
cally trialling the internationally validated
brief intervention, and secondly, because
the effect size of the alternative approach
would have been so small that we would
have needed very much larger numbers to
test its effectiveness. We had no intention of
“stumbling down something like this path”.
Nor do we agree that the blood tests were
“medicalising a social problem”. They were
intended not only to provide robust
outcome measures (a mark of a good trial),
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but also tangible evidence to clients of the
health effects of alcohol, shown from
previous research to be well received by
Aboriginal people.3,4 They were not a
requirement for participation.
Further, that we should have got around
the potentially off-putting business of
seeking informed consent by bypassing this
step almost defies comment. While trials of
some therapeutic interventions can be
undertaken blind with patient consent by
using placebos, this does not mean that
where blinding is not possible patient
consent should be done away with in order
to avoid a Hawthorne effect!
However, we do agree with Jamrozik on
one point — nothing about this study or our
report could reasonably “compound any
negative perceptions about Aboriginal
Medical Services and Aboriginal patients”.1
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TO THE EDITOR: I am responding to a
recent editorial by Jamrozik1 commenting
on a study proposed by Sibthorpe and
colleagues to assess a brief intervention for
hazardous use of alcohol by Indigenous
people in an urban setting.2
After two unsuccessful attempts to
recruit participants, the study was discon-
tinued and funds returned to the National
Health and Medical Research Council
(NHMRC) in 1998. Sibthorpe et al
identified their difficulties as primarily the
result of having overestimated the number
of suitable participants, for a number of
complex reasons.
Jamrozik’s criticisms rest disproportion-
ately with the NHMRC and are based on
procedures and processes in effect in 1996
and 1997, yet they are informed by
contemporary knowledge and wisdom.
This seems somewhat anomalous.
In 2000, the NHMRC revised its system
for assessing research applications. This
involved several developments which would
have had a direct impact on the assessment
of this application had they been instituted
in 1996. Some of these include:
■ the introduction of panels comprising 11
experts in the domain of the application;
■ the introduction of the Indigenous
Health Research Panel (IHRP), which
provides advice on cultural appropriateness,
community consultation and methods in
applications with an Indigenous component
(most members are Indigenous people);
and
■ the opportunity for IHRP to make
stipulations upon which funding is contin-
gent.
Also of significance was the establish-
ment of the Research Agenda Working
Group (RAWG), which oversaw the formu-
lation of intervention-based criteria. Collo-
quially known as the “Darwin criteria”,
these principles ensure that all Indigenous
research design has:
■ sufficient Indigenous community con-
sultation and participation;
■ transferability (of the methods to other
settings); and
■ sustainability (of resulting changes).
The NHMRC was disappointed that the
study by Sibthorpe et al did not proceed
and did not result in usable data to inform a
significant problem. However, it is also
important to recognise that unanticipated
outcomes, which can often lead to other,
very positive results, are an integral part of
the learning process.
The NHMRC has supported Australian
health and medical research since 1936. It
has a strong commitment to ensuring the
continuing evolution of its procedures and
practices. The new systems implemented in
2000 were designed to ensure the continu-
ing tradition of funding high quality,
relevant and applicable research.
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TO THE EDITOR: The recent article by
Sibthorpe et al1 and the accompanying
editorial2 on the issue of the failure of an
alcohol intervention trial in an Aboriginal
Health Service deal with problems facing all
primary care practitioners in the field of
“alcohol misuse” and should not be seen as
a peculiarly Aboriginal problem.
Firstly, despite what the academics may
tell us, administering an Alcohol Use
Disorders Identification Test (AUDIT)
questionnaire in general practice as a
screening measure meets with huge resist-
ance, no matter where you practice. Denial
of the disease-inducing potential of alcohol
is certainly not peculiar to Aboriginal
society.
Secondly, I find that the bulk of the
medical profession reinforces this commu-
nity denial by diagnosing conditions such as
diabetes, hypertension, obesity, anxiety,
depression and schizophrenia instead of
seeing these problems as being a manifesta-
tion of alcoholism or other “alcohol
misuse” until proven otherwise. Indeed, the
denial is so extreme that they tend to avoid
the term “alcoholism” altogether. Special-
ists are in even greater denial and are more
often a hindrance than a help to general
practitioners in this regard. As a conse-
quence, community leaders and affected
families are unable to develop effective
strategies for dealing with their problems.
What they get instead is increasing health-
care costs, hospital bed shortages, increas-
ing domestic violence, more “drug
problems” and more prisons.
So “GP reluctance or inability to follow
through...”2 is not surprising. Indeed,
denial of alcohol is so strong in the medical
profession that it is harder, in my experi-
ence, to get doctors and even medical
students (let along healthcare workers) to
attend open meetings of Alcholics Anony-
mous and Al-Anon than it is to persuade
affected people to do so.
Thirdly, general practice throughout
Australia has been organised for episodic,
fast-throughput care. People have become
so accustomed to this that they see any
attempt at a comprehensive preventive
approach to illness as odd, out of place,
time-consuming and even intrusive, espe-
cially so where alcohol and family histories
are concerned. That Aboriginal people are
no different from the rest of us in this regard
should cause no surprise.
1. Sibthorpe BM, Bailie RS, Brady MA, et al. The demise of a
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TO THE EDITOR: I read with interest the
recent correspondence in the Journal from
Del Mar and Glasziou.1 Their appeal to one
of their critics was to “abandon throwing
bricks from the sidelines and join us in
trying to help clinicians assess research
evidence in [a] timely fashion”. More
recently, their defence in relying on general-
ists, rather than experts, to assess the
evidence was, somewhat curiously, that “a
